Full Press Release Details
Can-Fite Enters Projected $3 Billion
Veterinary Osteoarthritis Market: Signs
Agreement with Vetbiolix for Development of Piclidenoson for Pets
Can-Fite PETACH TIKVA, Israel, June 28, 2021 --
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule
drugs that address inflammatory, cancer and liver diseases, today announced it has signed a development and commercialization agreement
with Vetbiolix, a France-based veterinary biotech company, for the development of Piclidenoson for the treatment of osteoarthritis in
companion animals including dogs and cats.
Vetbiolix will have the exclusive right to Piclidenoson
in the veterinary osteoarthritis market for two years, during which time Vetbiolix will conduct proof-of-concept studies and cover all
associated costs. If the studies yield positive data and Vetbiolix exercises its option to obtain the license from Can-Fite, then Vetbiolix
will be obligated to pay Can-Fite upfront and milestone payments, in addition to royalties on sales upon regulatory approval for veterinary
The canine osteoarthritis market is projected
to reach $3 billion by 2024. According to Grand View Research, the broader global companion animal health market is estimated at a value
of $20 billion in 2021 and is expected to grow to $27 billion by 2028.
Current treatments for canine osteoarthritis include
oral non-steroidal anti-inflammatory drugs (NSAIDs) which only treat symptoms and carry significant harmful side effects, and an injectable
disease modifying osteoarthritis drug (DMOAD) that targets the progression of the disease. Piclidenoson, an oral drug that has a favorable
safety profile in humans and in animal studies, offers a potentially safe and effective oral treatment for canine osteoarthritis.
"The veterinary market is a significant opportunity where our drugs may have an impact. Both the size of the market and the shorter
timelines to regulatory approval have the potential to result in milestone and royalty revenues for Can-Fite. We believe Piclidenoson's
safety and efficacy data in over 1,000 humans, as well as preclinical data from small animals, indicate it may offer relief to the growing
number of companion animals with osteoarthritis," stated Can-Fite VP Business Development Dr. Sari Fishman.
Matthieu Roquette, President at Vetbiolix commented,
"The quality of preclinical and clinical data generated by Can-Fite on Piclidenoson and its pharmacological profile make this highly
selective A3 Adenosine Receptor Agonist a drug candidate likely to meet the unmet veterinary medical need to date in the management of
osteoarthritis pathology in dogs and cats. Moreover, the mechanism of action of Piclidenoson makes this product a strong candidate for
a large spectrum of inflammatory disease indications affecting Pets. We are aiming to enter in veterinary regulatory development by the
end of 2022 based on clinical proof of concept data we will generate within the next 12 months."
In 2019, the U.S. Patent and Trademark Office
issued to the Can-Fite patent #10,265,337 titled "Use of A3 Adenosine Receptor Agonist in Osteoarthritis Treatment" for Piclidenoson
in the treatment of osteoarthritis in mammals.
Vetbiolix develops innovative products for treatment
and prevention of diseases affecting pets. As pharmaceutical and biotech companies research novel molecules and compounds for human medicine,
tests in different species often reveal exciting possibilities for pets. Vetbiolix has developed a unique approach focused on turning
this potential into innovative prescription medicines and care products for pets. To date, veterinarians have still few therapeutics and
real preventive care products at their disposal that have been specifically developed and approved for pets. Along with a virtual VetBiotech
organization, Vetbiolix exclusively focuses on clinical developments of prescription medicines, diagnostics, nutraceuticals and care products
for pets, thanks to its qualified external R&D partners in Europe & the US. Vetbiolix is supported by the Eurasant Bio-Incubator,
the northern France health cluster ranked among the top 20 best European incubators fostering pharm/biotech start-up development (Labiotech.eu
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. (NYSE American: CANF)
(TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion
dollar markets in the treatment of cancer, liver, inflammatory disease and COVID-19. The Company's lead drug candidate, Piclidenoson,
is currently in a Phase III trial for psoriasis and a Phase II study in the treatment of moderate COVID-19. Can-Fite's liver drug, Namodenoson,
is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and a Phase IIb trial for the
treatment of non-alcoholic steatohepatitis (NASH). Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast
Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept
to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy
in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,500 patients in clinical
studies to date. For more information please visit: www.can-fite.com.
Forward-Looking Statements
This press release may contain forward-looking
statements, about Can-Fite's expectations, beliefs or intentions regarding, among other things, market risks and uncertainties,
its product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time
to time, Can-Fite or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements
can be identified by the use of forward-looking words such as "believe," "expect," "intend," "plan,"
"may," "should" or "anticipate" or their negatives or other variations of these words or other comparable
words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may
be included in, but are not limited to, various filings made by Can-Fite with the U.S. Securities and Exchange Commission, press releases
or oral statements made by or with the approval of one of Can-Fite's authorized executive officers. Forward-looking statements relate
to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate
to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause Can-Fite's
actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could
cause Can-Fite's actual activities or results to differ materially from the activities and results anticipated in such forward-looking
statements. Factors that could cause our actual results to differ materially from those expressed or implied in such forward-looking statements
include, but are not limited to: our history of losses and needs for additional capital to fund our operations and our inability to obtain
additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the impact
of the COVID-19 pandemic; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate
development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies
or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals;
the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic
partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product
candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates
and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies
and our industry; statements as to the impact of the political and security situation in Israel on our business; and risks and other risk
factors detailed in Can-Fite's filings with the SEC and in its periodic filings with the TASE. In addition, Can-Fite operates in
an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control.
Can-Fite does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information,
future events or otherwise.